



PCT/AU000/00408

REC'D 29 MAY 2000

PCT


4

Patent Office  
Canberra

I, LEANNE MYNOTT, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 0202 for a patent by STEM CELL SCIENCES PTY LTD filed on 06 May 1999.

WITNESS my hand this  
Nineteenth day of May 2000

LEANNE MYNOTT  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES



**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

AUSTRALIA

---

*Patents Act 1990*

---

## PROVISIONAL SPECIFICATION

Invention Title:      **Improved nuclear transfer and nuclear addition (2)**

The invention is described in the following statement:

## IMPROVED NUCLEAR TRANSFER AND NUCLEAR ADDITION (2)

This invention relates to the generation of cells, embryos and animals by nuclear transfer and nuclear addition, including but not limited to the generation of transgenic animals.

5 Nuclear transfer or nuclear addition is the replacement or addition of the nucleus of one cell with that or to that of another. The ability to produce live offspring by nuclear transfer is an objective which has been sought for some time by animal breeders. The ability to produce cloned offspring in such a manner would enable the production of large numbers of identical offspring and the ability  
10 to genetically modify and/or select cell populations of the required genotype (e.g. sex or transgenic) prior to embryo reconstruction.

Whilst nuclear transfer has been described in some animals, the procedures used are often inefficient and have not yet been successfully applied to many species. Also, there are no examples of gene activity being modified in a  
15 large animal using nuclear transfer.

It is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties or deficiencies associated with the prior art.

In a first aspect of the present invention there is provided a method of preparing a reconstituted cell which method includes  
20 providing  
a donor nucleus,  
an exogenous nucleic acid molecule, and  
a recipient cell;  
optionally removing the nucleus from the recipient cell; and  
25 introducing the donor nucleus and the exogenous nucleic acid molecule into the recipient cell to produce the reconstituted cell.

In a second aspect of the present invention there is provided a method of generating a transgenic animal embryo which method includes

providing

an exogenous nucleic acid molecule, and  
a recipient cell;

- 5 optionally removing the nucleus from the recipient cell;  
introducing the donor nucleus and the exogenous nucleic acid molecule  
into the recipient cell to produce a reconstituted cell; and  
generating a transgenic animal embryo from the reconstituted cell.

The step of introducing the donor nucleus and the exogenous nucleic acid  
10 molecule into the enucleated or non-enucleated recipient cell is preferably  
performed by either:

- 1) introducing the exogenous nucleic acid molecule into the donor nucleus  
and then introducing the donor nucleus into the enucleated recipient cell or  
non-enucleated recipient cell;
- 15 2) combining the exogenous nucleic acid molecule with the donor nucleus and  
introducing the combined nucleic acid and nucleus into the enucleated  
recipient cell or non-enucleated recipient cell; or
- 3) introducing the exogenous nucleic acid and the donor nucleus separately  
into the enucleated recipient cell or non-enucleated recipient cell.

20 The exogenous nucleic acid molecule may be introduced into the donor  
nucleus, enucleated or non-enucleated recipient cell by any suitable means. For  
example, direct injection, electroporation or simple bathing of the nucleus or cell in  
a solution of the exogenous nucleic acid may be used.

In particularly preferred embodiments the exogenous nucleic acid is directly  
25 injected into the donor nucleus prior to nuclear transfer; or alternatively the donor  
nucleus and exogenous nucleic acid are combined and then injected into the  
recipient cell.

The exogenous nucleic acid molecule may be of any suitable type. Preferably it is a naked DNA molecule. Additionally exogenous RNA, mRNA, hybrids of DNA and RNA and ribozymes may be used. Whilst applicant does not wish to be restricted by theory, it is thought that when such molecules are introduced into or taken up by the donor nucleus, transgenesis may occur by random integration or by homologous recombination.

Alternatively, targeted transgenesis may be used, in which case the exogenous nucleic acid molecule includes 5' and/or 3' ends which direct the nucleic acid molecule to specific site(s) within the donor nucleus genome.

In a preferred form of these aspects of the invention, the methods include the further step of

maintaining the reconstituted cell in a suitable medium for a period sufficient to allow the cell to recover a substantially normal shape.

Applicant has discovered that the number of viable embryos produced may be significantly increased by permitting the reconstituted cell to be maintained in a quiescent state for a period sufficient to allow the cell to recover a substantially normal, e.g. generally circular, shape.

Whilst applicant does not wish to be restricted by theory, it is postulated that the quiescent period permits the cell to return to a more normal state after which cell fusion may proceed more efficiently.

The reconstituted cell may be maintained in a suitable medium preferably for a period of approximately 3 to 8 hours, more preferably approximately 4.5 to 6 hours.

It is desirable, however, that the quiescent period end before any, or any substantive division, ensues.

Activation occurs during fertilisation when the penetrating sperm triggers the resumption of meiosis. Activation is characterised by calcium oscillation,

release of cortical granules; extrusion of the second polar body, pronuclear fusion, and activation. Activation is not limited to, for example, ethanol, calcium ionophore or electrical stimulation to induce activation. Activation is performed prior to transfer of the donor nuclei.

- 5           In a preferred embodiment of the present invention, the methods may include the preliminary step of  
              subjecting the recipient cell to an activation step; and optionally  
              subsequently removing the nucleus from the activated cell.

Applicants have found, in this preferred embodiment, improved results  
10   where a preliminary activation step is undertaken.

Preferably the reconstituted cell is subsequently subjected to cell fusion.

Where the preferred preliminary activation step is not utilised the reconstituted cell may be subjected to a cell fusion/activation step. For example, where electrical pulses are utilised for cell fusion, the voltage may be selected to  
15   simultaneously initiate activation.

The reconstituted cell may be also subjected to simultaneous cell fusion/activation or a process of cell fusion followed later by activation.

The method of the present invention may include the further step of generating a transgenic animal from the transgenic animal embryo.

- 20           The donor nucleus may be of any suitable type and from any suitable species. The donor nucleus may be contained in a karyoplast or cell, although in certain forms of the present invention it is preferred that the donor nucleus is naked. The donor nucleus may be of embryonic, embryonal tumor, foetal or adult origin. Donor nuclei may be prepared by removing the nucleus and optionally a  
25   portion of the cytoplasm and plasma membrane surrounding it from early pre-implantation stage embryos (for example zygotes, 4- to 16- cell embryos) for example using microsurgery. When nuclei from more advanced embryonic cells

are used the whole blastomere may be transferred to the recipient cytoplasm. Embryonic or foetal fibroblasts may be used. Embryonic stem (ES) cells [isolated from inner cell mass (ICM) cells, embryonic disc (ED) cells or primordial germ cells (PGC)] may be used. A cell line derived from an embryonal tumor may be used  
 5 (eg. embryonal carcinoma (EC) or yolk sac tumor cells). Adult cells such as fibroblasts may also be used. In this case the whole cell may be fused to the recipient cytoplasm.

It is particularly preferred that the donor cells be at a particular stage in the cell cycle, for example  $G_0$ ,  $G_1$  or Sphase. Applicant has found that it is possible to  
 10 isolate populations of cells which are enriched for cells at each stage in the cell cycle by sorting the cells on the basis of size, for example using FACS. This avoids the use of stains, which are toxic to the cells. Staining can be used on a sample of each size-sorted population to identify what stage in the cell cycle that population is at.

15 The recipient cell may be of any suitable type and from any suitable species. Recipient cells may be *in vivo* or *in vitro* produced oocytes or cytoplasts may be prepared from *in vivo* or *in vitro* produced oocytes. Recipient cells may be oocytes or cytoplasts may be prepared from oocytes, for example arrested in the second metaphase of meiotic maturation (MII oocytes). Other sources of recipient  
 20 cells or cytoplasts include zygotes, fertilised oocytes, 2-cell blastomeres, and cell lines produced from gonads.

Cytoplast preparation involves the removal of the nucleus in a process referred to as enucleation. The nucleus may be removed by microsurgery. This may involve the removal of pronuclei or metaphase plate and surrounding  
 25 cytoplasm from zygotes or oocytes, for example by aspiration or embryo bisection. Such manipulation may follow incubation of the zygotes or oocytes in a microfilament inhibitor, for example cytochalasin B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.), that relaxes the cytoskeleton and allows the removal of a portion of membrane enclosed cytoplasm containing the pronuclei or metaphase  
 30 plate. Alternatively, nonphysical approaches such as inactivation of the chromosomes by UV (chemical) or laser irradiation may be used.

The donor nucleus may be transferred to the recipient cell by any suitable method. For example, fusion for example mediated by electrical pulses (electrofusion), chemical reagents such as polyethyleneglycol or the use of inactivated virus such as Sendai virus.

Preferably the donor nucleus is introduced under the zona pellucida.

Cytoplasm volume may be increased by fusing together zona pellucida free cytoplasm before, after or at approximately the same time as donor nucleus fusion.

10 An animal embryo may be generated from the reconstituted cell by any suitable method. Embryonic development may be initially *in vitro* and subsequently in a surrogate. Thus, the reconstituted cell may be initially cultured *in vitro* to produce an embryo and then the embryo may be transferred to a surrogate for subsequent development into an animal. *In vitro* culture of the  
15 reconstituted cells may be in any suitable medium.

The animal embryo or animal may be of any type, and includes bird, fish, reptile and mammalian (including ungulate and primate) embryos including human embryos, e.g. murine, bovine, ovine or porcine embryos. Preferably, the animal embryo is a porcine embryo, bovine embryo, murine embryo or human embryo.

20 In a preferred embodiment of this aspect of the present invention, the donor nucleus may be from an embryo that is itself the product of nuclear transfer or nuclear addition. This is known as serial nuclear transfer and/or addition.

Serial nuclear transfer and/or addition may improve the capacity of differentiated nuclei to direct normal development. Whilst applicant does not wish  
25 to be restricted by theory, serial nuclear transfer and/or addition is postulated to improve the developmental capacity of transplanted nuclei by allowing specific molecular components in the oocyte to assist in chromatin remodelling that is essential for nuclear reprogramming. Serial nuclear transfer and/or addition is not



restricted to a singular event but may be initiated on more than one occasion to sequentially improve conditions for chromatin remodelling, nuclear reprogramming and embryonic development.

The donor nucleus and recipient cell which are used in the method of the present invention may be of any suitable origin. Preferably, they are of porcine, bovine, ovine, rodent, avian, fish, reptile, murine or human origin.

The method of the present invention may be used to generate transgenic animals. For example, a new gene may be expressed and/or an existing gene may be deleted in the transgenic animal. The addition of new genes is technically less demanding than the deletion of existing genes.

As used in this specification the term "transgenic", in relation to animals and all other species, should not be taken to be limited to referring to animals containing in their germ line one or more genes from another species, although many transgenic animals will contain such a gene or genes. Rather, the term refers more broadly to any animal whose germ line has been the subject of technical intervention by recombinant DNA technology. So, for example, an animal in whose germ line an endogenous gene has been deleted or modified (either by modifying the gene product or pattern of expression) is a transgenic animal for the purposes of this invention, as much as an animal to whose germ line an exogenous nucleic acid sequence has been added.

The donor nucleus may be genetically modified by modifying, deleting or adding one or more genes. The gene(s) to be modified, deleted or added may be of any suitable type.

The process of modifying a gene may involve the introduction of one or more mutations in both copies of the target gene. Suitable cells may take up the mutation(s) and then be used to generate an animal. One copy of the gene may be disrupted in the cell and the resultant heterozygous animals bred with each other until one with both copies of the gene mutated is found. Alternatively, both

copies of the gene may be modified *in vitro*.

To target an endogenous gene rather than introduce random mutations, a DNA construct (transgene) including a nucleic acid sequence which is substantially isogenic to at least one or more portions of the target gene except for the introduction of the one or more mutations may, be used.

The targeting DNA may comprise a sequence in which the desired sequence modifications are flanked by DNA substantially isogenic with a corresponding target sequence in the genome to be modified. The substantially isogenic sequence is preferably at least about 97-98% identical with the corresponding target sequence (except for the desired sequence modifications), more preferably at least about 99.0-99.5% identical, most preferably about 99.6% to 99.9% identical. The targeting DNA and the target DNA preferably share stretches of DNA at least about 75 base pairs that are perfectly identical, more preferably at least about 150 base pairs that are perfectly identical, even more preferably at least about 500 base pairs that are perfectly identical. Accordingly, it is preferable to use targeting DNA derived from cells as closely related as possible to the cell being targeted; more preferably, the targeting DNA is derived from cells of the same haplotype as the cells being targeted. Most preferably, the targeting DNA is derived from cells of the same individual (or animal) as the cells being targeted. Preferably, the targeting DNA sequence comprises at least about 100-200 base pairs of substantially isogenic DNA, more preferably at least about 300-1000 base pairs of substantially isogenic DNA, even more preferably at least 1000-15000 base pairs of substantially isogenic DNA.

As used herein, the term isogenic or substantially isogenic DNA refers to DNA having a sequence that is identical with or nearly identical with a reference DNA sequence. Indication that two sequences are isogenic is that they will hybridise with each other under the most stringent hybridisation conditions (see e.g., Sambrook, J., Fritsch, E.F., Maniatis, T., (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbour Laboratory Press, New York); and will not exhibit sequence polymorphism (i.e. they will not have different sites for cleavage by restriction endonucleases). The term "substantially isogenic" refers to

DNA that is at least about 97-99% identical with the reference DNA sequence, and preferably at least about 99.5-99.9% identical with the reference DNA sequence and in certain cases 100% identical with the reference DNA sequence. Indications that two sequences are substantially isogenic is that they will still hybridise with  
 5 each other under the most stringent conditions (see Sambrook, J., et al., 1989) and that they will only rarely exhibit restriction fragment length polymorphism (RFLP) or sequence polymorphism (relative to the number that would be statistically expected for sequences of their particular length which share at least about 97-98% sequence identity). In general, a targeting DNA sequence and a  
 10 host cell sequence are compared over a window of at least about 75 consecutive nucleotides. DNA sequences compared between individuals of a highly inbred strain, such as the MHC inbred miniswine, are generally considered to be substantially isogenic even if detailed DNA sequence information is not available, if the sequence do not exhibit sequence polymorphisms by RFLP analysis.

15 Thus, the donor nucleus may be genetically modified by modifying an endogenous gene in the donor nucleus. The endogenous gene may be modified by introducing into said donor nucleus or by said donor nucleus taking up a DNA construct including a nucleic acid sequence which is substantially isogenic to at least one or more portions of the endogenous gene and includes one or more  
 20 mutations, such that there is homologous recombination between the DNA construct and the endogenous gene.

The introduction of new genetic material and the subsequent selection of cells harbouring the desired targeted integration requires expansion and clonal selection of each founder transgenic cell. A limitation to applying this process in  
 25 nuclear transplantation programs is the number of cell divisions which the transfected cell must undergo to provide sufficient material for molecular analysis of each transgenic colony and subsequent supply of nuclei for transfer. The great majority of cells suitable for *in vitro* genetic modification and subsequent nuclear transfer have limited *in vitro* propagation capacity. It is therefore desirable to utilise  
 30 transfection and selection systems which generate and/or identify correctly targeted clones at high efficiency and with limited requirement for *in vitro*

propagation.

A particularly efficient approach to selecting for correctly targeted clones is to use IRES gene trap targeting vectors, as described in Australian Patent 678234, the entire disclosure of which is incorporated herein by reference. The

5 IRES gene trap targeting vector may be selected from IRES-neo, IRES-lacZ, (TAA<sub>3</sub>) IRES-lacZ, (TAA<sub>3</sub>) IRES-lacZ lox neo-tk lox, (TAG<sub>3</sub>) IRES-lacZ/mcIneo, SA lacZ-IRES neo, SA (TAA<sub>3</sub>) IRES-nuclear lacZ, SA (TAA<sub>3</sub>) IRES-nuclear lacZ lox Gprt lox, IRES- $\beta$ geo, (TAA<sub>3</sub>) IRES- $\beta$ geo, SA IRES- $\beta$ geo SA Optimised IRES- $\beta$  geo, IRES-nuclear  $\beta$ geo, SA IRES-nuclear  $\beta$ geo, SA (TAA<sub>3</sub>) IRES-nuclear  $\beta$ geo,

10 SA Optimised IRES-nuclear  $\beta$ geo, IRES-zeo, SA IRES-zeo, IRES-hph, SA IRES-hph, IRES-hph-tk, IRES-bsd, SA IRES-bsd, IRES-puro. IRES gene trap targeting vectors provide a significant enhancement in gene targeting efficiency by eliminating a large proportion of random integration events. IRES gene trap targeting vectors rely upon functional integration into an actively transcribed gene

15 (such as the target gene) for expression of the selectable marker. Random integrations into non-transcribed regions of the genome are not selected.

In a preferred embodiment, it may be desirable to remove the selectable marker cassette from the targeted locus to eliminate expression of the eg. antibiotic resistance gene. One approach is to flank the IRES selectable marker

20 cassette with suitable DNA sequences which act as recombination sites following the addition of a suitable site-specific recombinase. One example of a suitable recombinase site is the lox site which is specific for the Cre recombinase protein. Another example of a suitable recombinase is the FLP/FRT recombinase system (O'Gorman, S., Fox, D.T., Wahl, G.M. (1991) Recombinase-mediated gene

25 activation and site-specific integration in mammalian cells. *Science* 251(4999), 1351-5).

High efficiency gene targeting and selection has a significant advantage in that suitably stringent selection systems, such as the IRES gene trap targeting vectors, can eliminate the need for biochemical analysis of clonal cell lines. In this

30 instance, individual nuclei from a pool of uncharacterised transgenic cells should generate offspring of the desired phenotype at a ratio equivalent to the selected

pool. The elimination of clonal selection may be particularly useful where only limited *in vitro* propagation is desirable or possible. One such instance includes the culture of embryonic nuclei for nuclear transfer. Embryonic nuclei are more efficient than latter stage somatic cells for generating live born offspring by nuclear transfer. However, totipotent embryonic cells can not be cultured for extended periods for any other species than mice. Nuclear recycling of embryonic nuclei provides an opportunity to maintain, expand and genetically manipulate multipotent cells from animals *in vitro*.

The DNA constructs may be engineered in bacteria and then introduced into the cells. The transgenes may be introduced into the cells by any suitable method. Preferred methods include direct injection, electroporation, liposomes or calcium phosphate precipitation. Direct injection is the preferred method for embryonic cells while electroporation is more suitable for embryonic fibroblast and embryonic stem cell cultures.

Whilst applicant does not wish to be restricted by theory, it is thought that regions of substantially isogenic DNA either side of the mutation drag the transgene to the target site where it recombines and introduces the mutation. It is further thought that the main contributing factor for increasing the efficiency of introducing a specific mutation in a given gene is the degree of similarity between the target DNA and the introduced DNA. Thus, it is preferred that the DNA is isogenic (genetically identical) not allogenic (genetically dissimilar) at the genetic locus that is to be targeted.

In a further aspect of the present invention there is provided a reconstituted animal cell produced by the methods of the present invention. Preferably the reconstituted animal cell is a porcine, murine, ovine, bovine, caprine or human cell.

In a further aspect of the present invention there is provided a transgenic animal embryo produced by the methods of the present invention. Preferably the transgenic animal embryo is a porcine, murine, ovine, bovine, caprine or human embryo.

In a still further aspect of the present invention there is provided a transgenic animal, wherein the transgenic animal is a porcine, murine, ovine, bovine, caprine or human animal.

- 5 The present invention will now be more fully described with reference to the accompanying Example. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.

### EXAMPLE

10 **Efficiency of Transgenesis in porcine embryos produced by Nuclear Transfer (NT) and Nuclear Addition (NA)**

Group	Oocytes	Fused (%)	Cleaved (%)	Blastocysts (%)	Transgenic (%)
NT	196	87(44.4)	42(48.2)	12(13.7)	1 (8.3)
NA	210	101(48.1)	50(79.2)	26(25.7)	3 (11.5)

The DNA construct used was pGalloway which is based on the porcine  $\alpha$ 1,3-galactosyltransferase gene

- 15 Finally, it is to be understood that various alterations, modifications and/or additions may be made without departing from the spirit of the present invention as outlined herein.

STEM CELL SCIENCES PTY LTD  
By their Registered Patent Attorneys  
Freehills Patent Attorneys

6 May 1999